Shandong Luoxin Pharmaceutical Group Stock Co.,Ltd. Risk Report
Explore Shandong Luoxin Pharmaceutical Group Stock Co.,Ltd. across six non‑financial risk dimensions:ESG, Workforce, News & Media, Cybersecurity, Legal & Regulatory, Operational. Unlock the full report, original sources and timelines, and enable continuous monitoring.
Summary
📜 Innovation & R&D
Shandong Luoxin Pharmaceutical Group Co., Ltd. is actively involved in drug research and development, focusing on various therapeutic markets. Their efforts in this space highlight their commitment to expanding their pharmaceutical offerings and maintaining a competitive edge.
- A joint venture agreement was entered by Luoxin with Aurobindo Pharma's subsidiary in China to enhance their capabilities 🗓 December 11, 2018.
- China's approval of HK Inno.N's therapy for gastroesophageal reflux reflects the dynamic regulatory environment Luoxin navigates 🗓 April 14, 2022.
- The erdosteine market is projected to grow significantly, with estimates indicating a market value surpassing USD 185 million by 2027; this expansion presents opportunities for Luoxin’s R&D endeavors 🗓 June 7, 2019.
🏗️ Operational & Business Continuity
Luoxin's operational endeavors demonstrate resilience and strategic planning in navigating rapidly changing market conditions. Continued attention to business continuity and market participation is essential in maintaining growth.
- The Velcade market, which includes competitors like Johnson & Johnson and Takeda, is predicted to experience substantial growth from 2020 to 2026, indicating potential operational risks associated with increased competition 🗓 September 18, 2020.
Profile
News & Media
Real‑time aggregation of trusted sources tracking company‑related events with sentiment and topic tags for rapid risk triage.
Sign up to unlock Shandong Luoxin Pharmaceutical Group Stock Co.,Ltd.’s complete news feed with sentiment and topic tags.
View Full ReportEntity List
Continuous third‑party screening across global sanctions, enforcement, and watchlist sources with unified entity resolution and real‑time alerts.
| Name | Issuer | Status |
|---|---|---|
| ACF List of War Enablers | Anti-Corruption Foundation | |
| African Development Bank Debarred Entities | African Development Bank Group | |
| Argentina Members of Parliament | Honorable Cámara de Diputados de la Nación Argentina | |
| Argentina RePET Sanctions | Ministerio de Justicia | |
| Armenia Public Officials and Associates | Hetq Online | |
| Asian Development Bank Sanctions | Asian Development Bank | |
| Australian Sanctions Consolidated List | Department of Foreign Affairs and Trade | |
| Democratic People's Republic Of Korea (North Korea) Sanctions Regime | Department of Foreign Affairs and Trade | |
| Former Federal Republic Of Yugoslavia Sanctions Regime | Department of Foreign Affairs and Trade | |
| Iran Sanctions Regime | Department of Foreign Affairs and Trade |
Sign up to unlock Shandong Luoxin Pharmaceutical Group Stock Co.,Ltd.’s sanctions, enforcement, and watchlist risk profile.
View Full ReportESG
Verification of declared ESG commitments and certifications with evidence links, score signals, and status updates across E, S, and G.
| Name | Status |
|---|---|
| Sustainable Finance Disclosure Regulation | |
| Global Reporting Initiative Standards | |
| EU Taxonomy Regulation | |
| EU Corporate Sustainability Reporting Directive | |
| California Transparency in Supply Chains Act | |
| EU Non-Financial Reporting Directive | |
| ISO 14001 | |
| Sustainability Accounting Standards Board Standards | |
| Task Force on Climate-related Financial Disclosures | |
| UN Guiding Principles on Business and Human Rights |
Sign up to unlock Shandong Luoxin Pharmaceutical Group Stock Co.,Ltd.’s ESG commitments, certifications, and controversy signals.
View Full ReportCybersecurity
Verification of adherence to recognized security standards, mapping control coverage and gaps affecting third‑party and supply‑chain risk.
| Certification | Status |
|---|---|
| General Data Protection Regulation | |
| Digital Operational Resilience Act | |
| Cybersecurity Maturity Model Certification | |
| NIST Cybersecurity Framework | |
| NIST 800-53 Revision 5 | |
| California Consumer Privacy Act | |
| ISO/IEC 27001 | |
| Health Insurance Portability and Accountability Act | |
| Payment Card Industry Data Security Standard | |
| Federal Information Security Modernization Act |
Sign up to unlock Shandong Luoxin Pharmaceutical Group Stock Co.,Ltd.’s security standards, control gaps, and exposure risks.
View Full ReportGet Shandong Luoxin Pharmaceutical Group Stock Co.,Ltd.'s full Non-Financial Risk Report
By signing up, you agree to our Terms and Privacy Policy.